Pipeline Progress at Momenta - Analyst Blog

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized.

Momenta Pharmaceuticals, Inc. ( MNTA ) recently got some good news when the company received Orphan Drug Designation for its oncology candidate, necuparanib (formerly M402), from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.

The designation from the FDA provides certain incentives, including federal grants, tax credits, waiver of filing fees and a seven-year marketing exclusivity period against competition once the candidate is approved.

Momenta expects to complete part A of its ongoing phase I/II study on necuparanib in combination with Abraxane and Gemzar. Data from the study is expected later in 2014. Momenta also expects to advance the candidate into the phase II of the study in the second half of 2014.

Momenta operates in three business areas- generics, biosimilars and drugs. Momenta's first commercial product was Enoxaparin sodium Injection, a generic version of Lovenox. It was developed in collaboration with Novartis' ( NVS ) Sandoz. The generic was approved in Jul 2010.

Meanwhile, Momenta's generic version of Teva Pharmaceutical Industries Ltd.'s ( TEVA ) Copaxone (M356) is currently under FDA review. On Mar 31, 2014, Teva announced that the U.S. Supreme Court will hear its appeal against a federal court decision that invalidated the claim of U.S. Patent 5,800,808 covering Copaxone. An outcome is expected by the fourth quarter of 2014.

Momenta carries a Zacks Rank #3 (Hold). Right now, Gilead Sciences ( GILD ) look attractive with a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

MOMENTA PHARMA (MNTA): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

TEVA PHARM ADR (TEVA): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More